Calcitonin Gene-Related Peptide (CGRP)-Targeted Treatments—New Therapeutic Technologies for Migraine
Migraine is ranked as the third most common disorder worldwide and is considered one of the most disabling neurological conditions. Its treatment has mostly relied on medications that were non-specifically developed for migraine, thus accompanied by low adherence, inadequate effectiveness and intole...
Main Authors: | Linda Sangalli, Stefania Brazzoli |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-01-01
|
Series: | Future Pharmacology |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-9879/3/1/8 |
Similar Items
-
Calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraines in adults
by: Eric R Ocheretyaner, et al.
Published: (2022-10-01) -
Antagonism of CGRP Signaling by Rimegepant at Two Receptors
by: Kylie S. Pan, et al.
Published: (2020-08-01) -
Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
by: Danuta Szkutnik-Fiedler
Published: (2020-12-01) -
Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide’s Motor-Stimulating and Prosecretory Function in the Intestine
by: Peter Holzer, et al.
Published: (2022-01-01) -
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
by: Fenne Vandervorst, et al.
Published: (2021-10-01)